SG10201505951VA - Quinoline derivatives and melk inhibitors containing the same - Google Patents
Quinoline derivatives and melk inhibitors containing the sameInfo
- Publication number
- SG10201505951VA SG10201505951VA SG10201505951VA SG10201505951VA SG10201505951VA SG 10201505951V A SG10201505951V A SG 10201505951VA SG 10201505951V A SG10201505951V A SG 10201505951VA SG 10201505951V A SG10201505951V A SG 10201505951VA SG 10201505951V A SG10201505951V A SG 10201505951VA
- Authority
- SG
- Singapore
- Prior art keywords
- same
- quinoline derivatives
- inhibitors containing
- melk inhibitors
- melk
- Prior art date
Links
- 229940124787 MELK inhibitor Drugs 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36951910P | 2010-07-30 | 2010-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201505951VA true SG10201505951VA (en) | 2015-08-28 |
Family
ID=45530500
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013006903A SG187633A1 (en) | 2010-07-30 | 2011-07-28 | Quinoline derivatives and melk inhibitors containing the same |
| SG10201505951VA SG10201505951VA (en) | 2010-07-30 | 2011-07-28 | Quinoline derivatives and melk inhibitors containing the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013006903A SG187633A1 (en) | 2010-07-30 | 2011-07-28 | Quinoline derivatives and melk inhibitors containing the same |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9120749B2 (en) |
| EP (1) | EP2597955B1 (en) |
| JP (1) | JP5849303B2 (en) |
| KR (1) | KR101826382B1 (en) |
| CN (1) | CN103153063B (en) |
| AU (1) | AU2011282588B2 (en) |
| BR (1) | BR112013002182B8 (en) |
| CA (1) | CA2806332C (en) |
| DK (1) | DK2597955T3 (en) |
| ES (1) | ES2565627T3 (en) |
| IL (1) | IL223871A (en) |
| MX (1) | MX342879B (en) |
| RU (1) | RU2582610C2 (en) |
| SG (2) | SG187633A1 (en) |
| TW (1) | TWI532483B (en) |
| WO (1) | WO2012016082A1 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2635279A4 (en) * | 2010-11-05 | 2014-10-29 | Glaxosmithkline Ip No 2 Ltd | Chemical compounds |
| CA2857346C (en) | 2012-01-19 | 2019-06-04 | Oncotherapy Science, Inc. | 1,5-naphthyridine derivatives and melk inhibitors containing the same |
| UY35464A (en) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | KRAS G12C COVALENT INHIBITORS. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| TWI659021B (en) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
| US10254283B2 (en) | 2013-11-12 | 2019-04-09 | Dana-Farber Cancer Institute, Inc. | Biomarker for MELK activity and methods of using same |
| JP6535007B2 (en) * | 2013-12-20 | 2019-06-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | Novel piperidine carboxamide compounds, process for their preparation and use |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| NZ732511A (en) * | 2014-12-15 | 2018-11-30 | Univ Michigan Regents | Small molecule inhibitors of egfr and pi3k |
| WO2016141296A1 (en) | 2015-03-04 | 2016-09-09 | Dana-Farber Caner Institute, Inc. | Tricyclic kinase inhibitors of melk and methods of use |
| EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (en) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | KRAS Condensed Tricyclic Inhibitors and Methods of Using Them |
| CN108026046B (en) * | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and/or NRAS proteins |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3325447A1 (en) * | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| TW201718536A (en) * | 2015-08-03 | 2017-06-01 | 必治妥美雅史谷比公司 | Heterocyclic compound which can be used as a TNFα modulator |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | Method for screening inhibitors of ras |
| EA038635B9 (en) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| RU2018126774A (en) * | 2015-12-22 | 2020-01-23 | Витэ Фармасьютикалз, Инк. | MENIN-MLL INTERACTION INHIBITORS |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| PT3484865T (en) | 2016-07-14 | 2022-11-03 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| SG11201901435UA (en) | 2016-08-31 | 2019-03-28 | Oncotherapy Science Inc | Monoclonal antibody against melk and utilization thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| JP2019534260A (en) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Heterocyclic compounds as inhibitors of RAS and methods of use thereof |
| US10577365B2 (en) * | 2016-12-23 | 2020-03-03 | Felicitex Therapeutics, Inc. | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| CN110869357A (en) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Compounds and methods of use thereof for treating cancer |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| MD3740475T2 (en) | 2018-01-17 | 2022-09-30 | Crinetics Pharmaceuticals Inc | Production process of somatostatin modulators |
| WO2019229765A1 (en) * | 2018-05-29 | 2019-12-05 | Council Of Scientific & Industrial Research, India | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CN109651355A (en) * | 2019-01-24 | 2019-04-19 | 广西师范大学 | 3- (the benzo five-membered heterocycle of 2-) -4- (the third amino of 3- dimethylamine) quinoline and its preparation method and application |
| CN109705037A (en) * | 2019-01-24 | 2019-05-03 | 广西师范大学 | 4-Aminoquinoline-3-carboxylate derivative and its preparation method and application |
| WO2020219729A1 (en) * | 2019-04-24 | 2020-10-29 | Children's Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
| EP4167982A4 (en) * | 2020-06-22 | 2024-08-07 | PMV Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION |
| WO2022015974A2 (en) * | 2020-07-15 | 2022-01-20 | St. Jude Children's Research Hospital, Inc. | Substituted 4-(3-aminoprop-1-yl)aminoquinoline analogs as modulators of melanoma-associated antigen 11 ubiquitin ligase |
| KR20230066379A (en) | 2020-09-09 | 2023-05-15 | 크리네틱스 파마슈티칼스, 인크. | Somatostatin modulator formulation |
| WO2022087083A1 (en) * | 2020-10-21 | 2022-04-28 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and their use |
| KR20230155422A (en) | 2020-12-22 | 2023-11-10 | 메카니스틱 테라퓨틱스 엘엘씨 | Substituted aminobenzylheteroaryl compounds as EGFR and/or PI3K inhibitors |
| WO2024220236A2 (en) * | 2023-04-21 | 2024-10-24 | University Of Georgia Research Foundation, Inc. | Hydroxylamine-based bcr-abl1 inhibitors for treatment of cancer |
| WO2025064853A1 (en) * | 2023-09-20 | 2025-03-27 | Momentum Therapeutics, Inc. | Ripk3 inhibitors and methods of use |
| WO2025147609A1 (en) * | 2024-01-05 | 2025-07-10 | Dewpoint Therapeutics, Inc. | Amino quinoline compounds and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1168801A (en) | 1966-05-13 | 1969-10-29 | May & Baker Ltd | Quinoline Derivatives |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| SE0101675D0 (en) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200423938A (en) | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| BRPI0410720A (en) | 2003-05-27 | 2006-06-20 | Pfizer Prod Inc | quinazolines and pyrido [3,4-d] pyrimidines as tyrosine kinase receptor inhibitors |
| DE602005025231D1 (en) | 2004-08-10 | 2011-01-20 | Oncotherapy Science Inc | GENES AND POLYPEPTIDES IN CONNECTION WITH BREAST CANCER DISEASES |
| EP2011885B1 (en) | 2005-02-10 | 2015-04-22 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| WO2007013665A2 (en) | 2005-07-27 | 2007-02-01 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| JP5249770B2 (en) * | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | Aminopyridines useful as kinase inhibitors |
| ATE478849T1 (en) | 2006-04-14 | 2010-09-15 | Astrazeneca Ab | 4-ANILINOCINOLINE-3-CARBONIC ACID AMIDES AS CSF-1R KINASE INHIBITORS |
| WO2007139496A1 (en) | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| PL2099796T3 (en) | 2006-11-30 | 2011-10-31 | Genentech Inc | Aza-indolyl compounds and methods of use |
| CN100540551C (en) * | 2007-02-01 | 2009-09-16 | 中国药科大学 | Quinoline derivatives, their preparation methods and their medicinal uses |
| PE20090717A1 (en) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| CN102573846B (en) * | 2009-08-17 | 2015-10-07 | 因特利凯公司 | Heterocyclic compounds and their uses |
| CA2857346C (en) * | 2012-01-19 | 2019-06-04 | Oncotherapy Science, Inc. | 1,5-naphthyridine derivatives and melk inhibitors containing the same |
-
2011
- 2011-07-28 MX MX2013001201A patent/MX342879B/en active IP Right Grant
- 2011-07-28 JP JP2013523213A patent/JP5849303B2/en active Active
- 2011-07-28 BR BR112013002182A patent/BR112013002182B8/en active IP Right Grant
- 2011-07-28 DK DK11813209.1T patent/DK2597955T3/en active
- 2011-07-28 CN CN201180047405.5A patent/CN103153063B/en active Active
- 2011-07-28 WO PCT/US2011/045792 patent/WO2012016082A1/en not_active Ceased
- 2011-07-28 US US13/813,134 patent/US9120749B2/en active Active
- 2011-07-28 RU RU2013108865/04A patent/RU2582610C2/en active
- 2011-07-28 SG SG2013006903A patent/SG187633A1/en unknown
- 2011-07-28 SG SG10201505951VA patent/SG10201505951VA/en unknown
- 2011-07-28 CA CA2806332A patent/CA2806332C/en active Active
- 2011-07-28 KR KR1020137005377A patent/KR101826382B1/en active Active
- 2011-07-28 AU AU2011282588A patent/AU2011282588B2/en active Active
- 2011-07-28 EP EP11813209.1A patent/EP2597955B1/en active Active
- 2011-07-28 ES ES11813209.1T patent/ES2565627T3/en active Active
- 2011-07-29 TW TW100126942A patent/TWI532483B/en active
-
2012
- 2012-12-25 IL IL223871A patent/IL223871A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011282588A1 (en) | 2013-03-21 |
| CA2806332A1 (en) | 2012-02-02 |
| IL223871A (en) | 2016-11-30 |
| MX342879B (en) | 2016-10-14 |
| US9120749B2 (en) | 2015-09-01 |
| RU2013108865A (en) | 2014-09-10 |
| EP2597955A1 (en) | 2013-06-05 |
| US20130217671A1 (en) | 2013-08-22 |
| JP2013532727A (en) | 2013-08-19 |
| KR101826382B1 (en) | 2018-02-06 |
| BR112013002182B8 (en) | 2023-02-28 |
| AU2011282588B2 (en) | 2016-01-07 |
| SG187633A1 (en) | 2013-03-28 |
| WO2012016082A1 (en) | 2012-02-02 |
| BR112013002182B1 (en) | 2022-05-03 |
| CN103153063B (en) | 2016-02-17 |
| CN103153063A (en) | 2013-06-12 |
| DK2597955T3 (en) | 2016-03-14 |
| TW201208686A (en) | 2012-03-01 |
| EP2597955A4 (en) | 2014-02-19 |
| RU2582610C2 (en) | 2016-04-27 |
| TWI532483B (en) | 2016-05-11 |
| ES2565627T3 (en) | 2016-04-06 |
| JP5849303B2 (en) | 2016-01-27 |
| BR112013002182A2 (en) | 2016-05-31 |
| MX2013001201A (en) | 2013-04-03 |
| KR20130094312A (en) | 2013-08-23 |
| HK1184331A1 (en) | 2014-01-24 |
| EP2597955B1 (en) | 2016-01-20 |
| CA2806332C (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL223871A (en) | Quinoline derivatives and melk inhibitors containing the same | |
| ZA201301120B (en) | Heterocyclic compound and use thereof | |
| ZA201300374B (en) | Ampk-activating heterocyclic compound and methods for using the same | |
| IL252108A0 (en) | Cdk inhibitors | |
| IL249669B (en) | Substituted 5-fluoro-1h-pyrazolopyridines and use thereof | |
| IL246600B (en) | Heterocyclic compounds and uses thereof | |
| EP2637669A4 (en) | Heterocyclic compounds and uses thereof | |
| ZA201305531B (en) | Selective glycosidase inhibitors and uses thereof | |
| IL220939A0 (en) | Compounds and methods | |
| EP2523664A4 (en) | Compounds and methods | |
| IL222288A0 (en) | Heterocyclic compounds and their uses | |
| IL220812A0 (en) | Compounds and methods | |
| IL233529A0 (en) | 1,5-naphthyridine derivatives and melk inhibitors containing the same | |
| ZA201300036B (en) | Banzamide derivatives and their use as hsp90 inhibitors | |
| EP2523560A4 (en) | Compounds and methods | |
| AP2012006419A0 (en) | Aminoquinoline derivatives | |
| PT2597084T (en) | N-hydroxyformamide derivative and pharmaceutical containing same | |
| SI2655388T1 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201018597D0 (en) | Inhibitors | |
| EP2626349A4 (en) | Amine compound and use for same |